Loading…
Immune protection conferred by recombinant MRLC (myosin regulatory light chain) antigen in TiterMax Gold® adjuvant against experimental fasciolosis in rats
Highlights • Fasciola hepatica in an important animal and human pathogen. • First experimental trial evaluating Fasciola hepatica MRLC antigen in a rodent model. • 51.0% immune protection conferred.
Saved in:
Published in: | Vaccine 2017-01, Vol.35 (4), p.663-671 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Highlights • Fasciola hepatica in an important animal and human pathogen. • First experimental trial evaluating Fasciola hepatica MRLC antigen in a rodent model. • 51.0% immune protection conferred. |
---|---|
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2016.11.092 |